D.E. Shaw & Co
HZNP

D.E. Shaw & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

D.E. Shaw & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,900
Closed -$236K – 3948
2015
Q4 		$236K Sell
10,900
-50,000
-82% -$973K ﹤0.01% 3488
2015
Q3 		$1.21M Buy
60,900
+50,000
+459% +$1.58M ﹤0.01% 2474
2015
Q2 		$379K Buy
+10,900
New +$333K ﹤0.01% 3309

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's HZNP Position: Q4 2023 in Review

D.E. Shaw & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,718,246 shares — an estimated $546M sold.

D.E. Shaw & Co first reported a position in HZNP in Q3 2013 and held it in 40 quarters. The position peaked at $546M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • D.E. Shaw & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 4,718,246 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $546M.
  • D.E. Shaw & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 40 quarters.
  • D.E. Shaw & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $546M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.